-
ACAP Health partners with Regenexx to reduce orthopedic surgery costs — 3 insights
Dallas-based consulting company ACAP Health partnered with interventional orthopedic physician network Regenexx to reduce orthopedic surgery costs for employers. -
Kuros Biosciences to present case study results of MagnetOs Granules — 3 insights
Kuros Biosciences will present results from clinical case studies of MagnetOs Granules at the 15th annual State of Spine Surgery Think Tank on June 21 to June 23 in Aruba. -
Dr. Mark McFarland performs spine surgery with SpineFrontier LES Technology & NanoFuse Biologics: 4 highlights
Spine surgeon Mark McFarland, DO, performed a surgery with SpineFrontier's REmind pedicle screw system and LES P-LIFT interbody cages as well as NanoFuse Bioactive Matrix. -
Wright Medical wins premarket approval for biologic alternative — 6 insights
The FDA granted Wright Medical Group premarket approval for its Augment Injectable Bone Graft. -
New study will compare Kuros Biosciences' MagnetOs, autograft for spinal fusion: 3 insights
The University Medical Center Utrecht in the Netherlands will begin a study comparing Kuros Biosciences' MagnetOs with autologous bone in posterolateral spinal fusion. -
Cerapedics earns 2018 MedTech Breakthrough Award for i-FACTOR bone graft— 5 highlights
Cerapedics earned the 2018 MedTech Breakthrough Award for Best New Surgical Technology Solution. -
Edison Healthcare offers employees biologic-based alternatives to orthopedic surgery: 3 insights
Tulsa, Okla.-based Edison Healthcare partnered with Regenexx to offer its employees alternatives to orthopedic surgery. -
NuVasive launches AttraX Scaffold biologic: 4 things to know
NuVasive launched the AttraX Scaffold in the U.S. for use in the posterolateral spine to promote fusion. -
Spine biologics market to grow at CAGR of 4.09% through 2022
The global spine biologics market is expected to grow at a compound annual growth rate of 4.09 percent from 2018 to 2022, according to a 360 Market Updates report. -
3 things to know about Lattice Biologics
Lattice Biologics is a regenerative medicine company that develops biologic allograft products for bone, skin and cartilage solutions. -
8 key surgeon Q&As on biologics in orthopedics & spine
Here are eight Q&As on the application of biologics in orthopedics and spine. -
International Stem Cell Corp. to launch joint supplement for osteoarthritis pain in Q3 2018
International Stem Cell Corporation plans to launch its advanced joint supplement for the treatment of osteoarthritis-related joint pain in the third quarter of 2018. -
How Dr. Kevin Stone helped Super Bowl champion Tracy Porter make a comeback — 6 details
Tracy Porter, the football legend notorious for sealing the New Orleans Saints' Super Bowl win in 2010, struggled with persistent knee pain for several seasons. -
Study: First-in-human neural stem cell transplantation shows promise for spinal cord injury treatment — 5 takeaways
A first-in-human phase I clinical trial in which neural stem cells were transplanted into chronic spinal cord injury patients produced improved motor and sensory function in three of four subjects with no adverse effects, according to results published in Cell Stem Cell. -
How PolarityTE aims to bring 'an entirely new treatment paradigm' to orthopedics & spine — 7 Qs with Dr. Ned Swanson
While working in a burn unit at Baltimore-based John Hopkins University School of Medicine, PolarityTE founders Ned Swanson, MD, and Denver Lough, MD, PhD, grappled with the limited treatment options for patients. Inspired to provide new methods, they left their plastic surgery residency program and launched a portfolio of regenerative products. -
Stem cell banking an unclear path for regenerative medicine: 4 notes
LifeVault Bio's GoodCell kit allows customers to bank their stem cells for future use, STAT reports, but not all stem cell researchers are on board. -
Fidelity International invests $5.2M in stem cell, regenerative medicine company — 3 insights
Global asset manager Fidelity International invested $5.2 million in Cynata Therapeutics, an Australian stem cell and regenerative medicine company, Business Insider Australia reports. -
The global spine biologics market to grow at CAGR of 4.1% through 2022: 3 things to know
The global spine biologics market is forecasted to grow at a compound annual growth rate of 4.09 percent between 2018 and 2022, according to a Technavio report. -
DiscGenics treats 1st patient in degenerative disc disease clinical trial: 5 things to know
DiscGenics principal investigator Domagoj Coric, MD, of Carolina Neurosurgery and Spine Associates in Charlotte, N.C., treated the first patient in the phase 1/phase 2 clinical trial of IDCT. -
3 things to know about Organogenesis
Organogenesis is a regenerative medicine company based in Canton, Mass., focused on developing products for the wound care, surgical and sports medicine markets.
Page 31 of 34